Welcome!

Thank you for being part of CANCER FUND's Screening Committee QUICK LOOKS program. With your help, we can do great things together!

Question Title

* 1. What's your email address? This information will allow us to connect your responses to your profile.

STEP 1: READ

SUMMARY:

REGALGENE is developing a safe, orally administered microtubule targeting agent that passively crosses the blood-brain barrier (BBB and is therapeutically effective for the treatment of high-grade glioma and other cancers that metastasize into the brain.
  • They have achieved proof of concept in animal models.
  • They are actively raising funds to take their first product through the regulatory studies necessary to enter clinical trials in mid 2023.

FOCUS AREA:
Therapies & Management

CANCER FOCUS:
High-Grade Glioma
Metastatic breast cancer
Metastatic lung cancer

KEY BENEFITS:
Oral Administration
BBB Penetration
Well-Tolerated
STEP 2: RATE

Question Title

* 2. How would you rank the potential impact of RELAGENE on cancer patients with high grade Glioma or metastatic brain cancer?

Question Title

* 3. Assuming REGLAGENE can deliver what they promise, how different do you perceive their solution to be versus other options you are familiar with?

Question Title

* 4. Based on what you know, do you think REGLAGENE deserves further consideration for investment by Cancer Fund?

STEP 3: RAVE. OR RANT. OR NOT. (Optional)

Question Title

* 5. Do you have any other feedback you want to give us on REGLAGENE?

Question Title

* 6. Would you like to share any final comments with us about CANCER FUND or QUICK LOOKS?

Or you can ask questions here and we'll follow up with you directly.

T